Literature DB >> 16203055

[Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)].

F Bouali1, A Berrah, D Si Ahmed-Bouali, F Harrieche, M Benhalima, R M Hamladji, M Arrada.   

Abstract

UNLABELLED: The association of myelodysplastic syndromes (MDS) with auto-immune diseases and humoral disorders have already been reported. In this prospective study we tried to estimate type and the frequency of immunological associated diseases among patients affected by MDS. PATIENTS-
METHODS: In this prospective study, auto-immune disease and humoral immunity disorders were systematically searched during MDS and conversely MDS searched during cytopenia. All MDS secondary to chemotherapy and the children's MDS were excluded. The MDS diagnosis was established according to FAB criteria and patients were classified in two groups A or B according to presence (group A) or not (group B) of dysimmune manifestations.
RESULTS: Forty patients(19 males and 21 females, mean age of 56,6 years) with MDS have been enrolled during this period (group A: 20 patients). Associated diseases are following: systemic lupus erythematosus (three), lupus-like syndrome(one), sarcoidisis(one), Sjogrën syndrome(one), polyarthritis (two), chronic liver diseases (three), autoimmune thyroid diseases (two), pyoderma gangrenosum (one), Crohn's disease(one), haemolytic anaemia (one), and pericardial effusion(one).
CONCLUSION: A wide spectrum of auto-immune manifestations is frequently reported in myelodysplastic syndromes. Further studies are necessary for discuss the current physiopathological hypothesis with their therapeutic relevance.

Entities:  

Mesh:

Year:  2005        PMID: 16203055     DOI: 10.1016/j.revmed.2005.06.012

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  7 in total

1.  [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

Authors:  Jutta G Richter; Pascal Gossen; Ulrich Germing; Sabine Blum; Barbara Hildebrandt; Stefan Braunstein; Dörte Huscher; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

3.  Inflammatory Rheumatologic disorders in patients with Myelodysplastic Syndromes: A cross-sectional study.

Authors:  Maryam Mobini; Ramin Shekarriz; Reza Ali Mohammad Pour; Shahrzad Zakeri
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-01-01

4.  Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.

Authors:  Bradley T Williamson; Lynda Foltz; Heather A Leitch
Journal:  Hematol Rep       Date:  2016-05-10

5.  Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.

Authors:  Bradley T Williamson; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2016-01-20

6.  Commentary: 'Case Report: A Rare Case of Elderly-Onset Adult Onset Still's Disease in a Patient With Systemic Lupus Erythematous'.

Authors:  Marion Delplanque; Arsène Mekinian; Sophie Georgin-Lavialle
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 7.  Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases.

Authors:  Arsène Mekinian; Thorsten Braun; Olivier Decaux; Géraldine Falgarone; Eric Toussirot; Loic Raffray; Mohamed Omouri; Bruno Gombert; Benoit De Wazieres; Anne-Laure Buchdaul; Jean-Marc Ziza; David Launay; Guillaume Denis; Serge Madaule; Christian Rose; Eric Grignano; Pierre Fenaux; Olivier Fain
Journal:  Medicine (Baltimore)       Date:  2014-01       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.